Recarbrio, an antibiotic designed to treat infections caused by Gram negative bacteria, has been approved for a new indication by the US Food and Drug Administration. This is to treat both hospital acquired bacterial pneumonia and ventilator associated bacterial pneumonia which can cause chest pain and an increased need for oxygen.
